HSF2は,増殖と侵入の間のステージ固有のスイッチとして作用することで,乳がんの進行を促します
Jenny C Pessa1,2, Oona Paavolainen2,3,4, Hendrik S E Hästbacka1,2
1Faculty of Science and Engineering, Cell Biology, Åbo Akademi University, Turku, Finland.
Science advances
|September 3, 2025
まとめ
熱ショック因子2 (HSF2) は乳がんの細胞増殖を早期に促進する. 変換成長因子β (TGF-β) 信号はHSF2を減少させ,がん細胞の侵入を可能にします.
科学分野:
- 腫瘍学
- 分子生物学
- 細胞生物学
背景:
- 乳がんの進行には複雑な細胞表型変化が伴う.
- ストレス保護性転写因子である熱ショック因子2 (HSF2) の乳がん発生における役割は十分に理解されていません.
- HSF2は様々な癌と関連していることが知られている.
研究 の 目的:
- 乳がん進行中のHSF2発現と活性における動的変化を調査する.
- 乳がんにおけるHSF2機能を調節する分子メカニズムを解明する.
- 乳がんの発達におけるHSF2の段階特有の役割を決定する.
主な方法:
- ヒトの乳腺腫瘍とマウスの異種移植の分析
- 免疫ヒストロケミストは,HSF2の発現,局所化,およびKi67との共同発現を評価する.
- 細胞ベースのモデルで,成長因子β (TGF-β) の信号変換がHSF2に与える影響を研究する.
- 細胞フェノタイプへの影響を観察するためにHSF2レベル (子宮の外表) を操作する.
主要な成果:
- 増殖マーカーKi67と相関する,本位管がん (DCIS) のHSF2発現と核局在の増加.
- マウスの異種移植では,DCISから侵入性がんへの移行時に,HSF2の局所化は核から細胞質に移行する.
- 変形成長因子β (TGF-β) 信号はHSF2をダウンレギュレーションし,侵入性細胞フェノタイプの獲得を容易にする.
- HSF2レベルを回復させることで,TGF-βシグナル伝達によって誘発された侵襲的なフェノタイプを無効化しました.
結論:
- HSF2は乳がんの特定段階の調節剤として働き,初期段階の増殖を促進し,潜在的に侵入を抑制します.
- 成長因子β (TGF-β) 信号の変換は,HSF2の活動と局所化を調節する重要なメカニズムであり,増殖から侵入へのスイッチを駆動します.
- HSF2またはTGF-βシグナル伝達経路をターゲットにすることで,乳がんの治療に新しい治療戦略を提供することができる.
関連する概念動画
02:07Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
02:40Cancer Stem Cells and Tumor Maintenance
5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
02:38Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K